{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:42:10Z","timestamp":1794375730584,"version":"4.9.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2021YFA1100800"],"award-info":[{"award-number":["2021YFA1100800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20418"],"award-info":[{"award-number":["U23A20418"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470225"],"award-info":[{"award-number":["82470225"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foundation of Shanghai Shen Kang Hospital Development Center","award":["SHDC2023CRD021"],"award-info":[{"award-number":["SHDC2023CRD021"]}]},{"name":"Foundation of Shanghai Shen Kang Hospital Development Center","award":["SHDC2023CRS030"],"award-info":[{"award-number":["SHDC2023CRS030"]}]},{"name":"Cultivation project of National Natural Science Foundation of Shanghai Tongji Hospital","award":["GJPY2314"],"award-info":[{"award-number":["GJPY2314"]}]},{"name":"Cultivation project of National Natural Science Foundation of Shanghai Tongji Hospital","award":["GJPY2332"],"award-info":[{"award-number":["GJPY2332"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07281-w","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:04:10Z","timestamp":1762524250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sequential PD-1 inhibitors as consolidative therapy post-CD19 CART in relapsed\/refractory NHL: a propensity score matching cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Bin","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huina","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aibin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"10254","key":"7281_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene Maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352.","journal-title":"Lancet"},{"issue":"1","key":"7281_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"1","key":"7281_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","volume":"21","author":"J Lu","year":"2022","unstructured":"Lu J, Jiang G. The journey of CAR-T therapy in hematological malignancies. Mol Cancer. 2022;21(1):194.","journal-title":"Mol Cancer"},{"issue":"3","key":"7281_CR4","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.jaci.2024.12.1066","volume":"155","author":"B Ca\u00ebl","year":"2025","unstructured":"Ca\u00ebl B, B\u00f4le-Richard E, Garnache Ottou F, Aubin F. Chimeric antigen receptor-modified T-cell therapy: recent updates and challenges in autoimmune diseases. J Allergy Clin Immunol. 2025;155(3):688\u2013700.","journal-title":"J Allergy Clin Immunol"},{"issue":"16","key":"7281_CR5","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138.","journal-title":"Blood"},{"issue":"1","key":"7281_CR6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41392-023-01626-x","volume":"8","author":"Y Fang","year":"2023","unstructured":"Fang Y, Zhang MC, He Y, Li C, Fang H, Xu PP, et al. Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8(1):381.","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"7281_CR7","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1182\/bloodadvances.2020001727","volume":"4","author":"L Meriranta","year":"2020","unstructured":"Meriranta L, Pasanen A, Alkodsi A, Haukka J, Karjalainen-Lindsberg ML, Lepp\u00e4 S. Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma. Blood Adv. 2020;4(15):3742\u201353.","journal-title":"Blood Adv"},{"issue":"28","key":"7281_CR8","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7281_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41375-021-01347-6","volume":"36","author":"A Rossi","year":"2022","unstructured":"Rossi A, Orecchioni S, Falvo P, Tabanelli V, Baiardi E, Agostinelli C, et al. Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. Leukemia. 2022;36(1):197\u2013209.","journal-title":"Leukemia"},{"issue":"5","key":"7281_CR10","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1158\/2159-8290.CD-22-0998","volume":"13","author":"MM Hoppe","year":"2023","unstructured":"Hoppe MM, Jaynes P, Shuangyi F, Peng Y, Sridhar S, Hoang PM, et al. Patterns of oncogene coexpression at Single-Cell resolution influence survival in lymphoma. Cancer Discov. 2023;13(5):1144\u201363.","journal-title":"Cancer Discov"},{"issue":"7938","key":"7281_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41586-022-05249-0","volume":"612","author":"T Funnell","year":"2022","unstructured":"Funnell T, O\u2019Flanagan CH, Williams MJ, McPherson A, McKinney S, Kabeer F, et al. Single-cell genomic variation induced by mutational processes in cancer. Nature. 2022;612(7938):106\u201315.","journal-title":"Nature"},{"key":"7281_CR12","doi-asserted-by":"publisher","first-page":"216766","DOI":"10.1016\/j.canlet.2024.216766","volume":"588","author":"S Chauhan","year":"2024","unstructured":"Chauhan S, Jaiswal S, Jakhmola V, Singh B, Bhattacharya S, Garg M, et al. Potential role of p53 deregulation in modulating immune responses in human malignancies: A paradigm to develop immunotherapy. Cancer Lett. 2024;588:216766.","journal-title":"Cancer Lett"},{"issue":"1","key":"7281_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-022-01249-9","volume":"15","author":"Y Zhuang","year":"2022","unstructured":"Zhuang Y, Che J, Wu M, Guo Y, Xu Y, Dong X, et al. Altered pathways and targeted therapy in double hit lymphoma. J Hematol Oncol. 2022;15(1):26.","journal-title":"J Hematol Oncol"},{"key":"7281_CR14","doi-asserted-by":"crossref","unstructured":"Bin X, Yifan L, Jie Z, Lili Z, Shiguang Y, Yan L, et al. CD19 CAR-T treatment shows limited efficacy in r\/r DLBCL with double expression and TP53 alterations. Cytotherapy. 2024;26(12).","DOI":"10.1016\/j.jcyt.2024.07.011"},{"issue":"9","key":"7281_CR15","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med. 2022;28(9):1872\u201382.","journal-title":"Nat Med"},{"issue":"5","key":"7281_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint Blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471\u201382.","journal-title":"Cancer Cell"},{"key":"7281_CR17","doi-asserted-by":"crossref","unstructured":"Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng RH, Leggett N, et al. PD-L1 Blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163\u2009+\u2009M2 macrophages. J Immunother Cancer. 2022;10(6).","DOI":"10.1136\/jitc-2021-004400"},{"issue":"20","key":"7281_CR18","first-page":"2470","volume":"141","author":"C Roddie","year":"2023","unstructured":"Roddie C, Lekakis LJ, Marzolini MAV, Ramakrishnan A, Zhang Y, Hu Y, et al. Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma. Blood. 2023;141(20):2470\u201382.","journal-title":"Blood"},{"key":"7281_CR19","doi-asserted-by":"crossref","unstructured":"Liu J, Zhang F, Yu J, Zhao Q. Programmed death-ligand 1 expression on CD22-specific chimeric antigen receptor-modified T cells weakens antitumor potential. MedComm (2020). 2022;3(2):e140.","DOI":"10.1002\/mco2.140"},{"issue":"1","key":"7281_CR20","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1038\/s41467-024-47799-z","volume":"15","author":"I Andreu-Saumell","year":"2024","unstructured":"Andreu-Saumell I, Rodriguez-Garcia A, M\u00fchlgrabner V, Gimenez-Alejandre M, Marzal B, Castellsagu\u00e9 J, et al. CAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated Inhibition. Nat Commun. 2024;15(1):3552.","journal-title":"Nat Commun"},{"issue":"1","key":"7281_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-021-01044-y","volume":"14","author":"Y Liang","year":"2021","unstructured":"Liang Y, Liu H, Lu Z, Lei W, Zhang C, Li P, et al. CD19 CAR-T expressing PD-1\/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies. J Hematol Oncol. 2021;14(1):26.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"7281_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/bloodadvances.2023011287","volume":"8","author":"AV Hirayama","year":"2024","unstructured":"Hirayama AV, Kimble EL, Wright JH, Fiorenza S, Gauthier J, Voutsinas JM, et al. Timing of anti-PD-L1 antibody initiation affects efficacy\/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Adv. 2024;8(2):453\u201367.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"7281_CR23","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1182\/blood-2023-180500","volume":"142","author":"X Bin","year":"2023","unstructured":"Bin X, Xiu L, Yifan L, Shiguang Y, Lili Z, Shaoguang L, et al. CAR T-Cell therapy combined with PD-1 inhibitors significantly improve the efficacy and prognosis of r\/r DLBCL with TP53 alterations. Blood. 2023;142(Supplement 1):3515.","journal-title":"Blood"},{"issue":"1","key":"7281_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275\u201382.","journal-title":"Blood"},{"issue":"12","key":"7281_CR25","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1001\/jamaoncol.2020.4643","volume":"6","author":"H Hayashi","year":"2020","unstructured":"Hayashi H, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, et al. Site-Specific and targeted therapy based on molecular profiling by Next-Generation sequencing for cancer of unknown primary site: A nonrandomized phase 2 clinical trial. JAMA Oncol. 2020;6(12):1931\u20138.","journal-title":"JAMA Oncol"},{"issue":"1","key":"7281_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1182\/blood.V94.1.225.413k24_225_232","volume":"94","author":"T Fioretos","year":"1999","unstructured":"Fioretos T, Str\u00f6mbeck B, Sandberg T, Johansson B, Billstr\u00f6m R, Borg A, et al. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. Blood. 1999;94(1):225\u201332.","journal-title":"Blood"},{"issue":"3","key":"7281_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for blood and marrow transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE) and the European haematology association (EHA). Ann Oncol. 2022;33(3):259\u201375.","journal-title":"Ann Oncol"},{"issue":"4","key":"7281_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"7281_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.20892\/j.issn.2095-3941.2022.0585","volume":"20","author":"P Li","year":"2023","unstructured":"Li P, Liu Y, Liang Y, Bo J, Gao S, Hu Y, et al. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Biol Med. 2023;20(2):129\u201346.","journal-title":"Cancer Biol Med"},{"issue":"27","key":"7281_CR30","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"key":"7281_CR31","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2022. https:\/\/www.R-project.org\/.12c"},{"issue":"16","key":"7281_CR32","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1158\/0008-5472.CAN-23-1484","volume":"83","author":"S Ortiz-Espinosa","year":"2023","unstructured":"Ortiz-Espinosa S, Srivastava S. Bursting tumor bubbles to improve CAR T-cell therapy. Cancer Res. 2023;83(16):2637\u20139.","journal-title":"Cancer Res"},{"key":"7281_CR33","doi-asserted-by":"crossref","unstructured":"Ba H, Dai Z, Zhang Z, Zhang P, Yin B, Wang J, et al. Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers. J Immunother Cancer. 2023;11(1).","DOI":"10.1136\/jitc-2021-003837"},{"issue":"8","key":"7281_CR34","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO-24-02081","volume":"43","author":"S Ouladan","year":"2025","unstructured":"Ouladan S, Orouji E. Chimeric antigen Receptor-T cells in colorectal cancer: pioneering new avenues in solid tumor immunotherapy. J Clin Oncol. 2025;43(8):994\u20131005.","journal-title":"J Clin Oncol"},{"issue":"690","key":"7281_CR35","doi-asserted-by":"publisher","first-page":"eabk1900","DOI":"10.1126\/scitranslmed.abk1900","volume":"15","author":"D Meyran","year":"2023","unstructured":"Meyran D, Zhu JJ, Butler J, Tantalo D, MacDonald S, Nguyen TN, et al. T(STEM)-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. Sci Transl Med. 2023;15(690):eabk1900.","journal-title":"Sci Transl Med"},{"key":"7281_CR36","doi-asserted-by":"crossref","unstructured":"Krueger C, Sabapathy K. p53 prophylactic therapy for cancer prevention. Cell Death Differ. 2025.","DOI":"10.1038\/s41418-025-01538-z"},{"issue":"1","key":"7281_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41408-024-01090-y","volume":"14","author":"R Norris","year":"2024","unstructured":"Norris R, Jones J, Mancini E, Chevassut T, Simoes FA, Pepper C, et al. Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data. Blood Cancer J. 2024;14(1):105.","journal-title":"Blood Cancer J"},{"issue":"1","key":"7281_CR38","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41408-024-01153-0","volume":"14","author":"S Mato","year":"2024","unstructured":"Mato S, Castrej\u00f3n-de-Anta N, Colmenero A, Carit\u00e0 L, Salmer\u00f3n-Villalobos J, Ramis-Zaldivar JE, et al. MYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt lymphoma. Blood Cancer J. 2024;14(1):171.","journal-title":"Blood Cancer J"},{"issue":"3","key":"7281_CR39","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00262-020-02708-3","volume":"70","author":"DJ Landsburg","year":"2021","unstructured":"Landsburg DJ, Koike A, Nasta SD, Svoboda J, Schuster SJ, Wasik MA, et al. Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas. Cancer Immunol Immunother. 2021;70(3):869\u201374.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"7281_CR40","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1158\/0008-5472.CAN-22-0232","volume":"83","author":"R Dhanasekaran","year":"2023","unstructured":"Dhanasekaran R, Hansen AS, Park J, Lemaitre L, Lai I, Adeniji N, et al. MYC overexpression drives immune evasion in hepatocellular carcinoma that is reversible through restoration of Proinflammatory macrophages. Cancer Res. 2023;83(4):626\u201340.","journal-title":"Cancer Res"},{"issue":"1","key":"7281_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-022-00924-0","volume":"7","author":"J Wei","year":"2022","unstructured":"Wei J, Xiao M, Mao Z, Wang N, Cao Y, Xiao Y, et al. Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. Signal Transduct Target Therapy. 2022;7(1):101.","journal-title":"Signal Transduct Target Therapy"},{"issue":"4","key":"7281_CR42","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.21.02143","volume":"40","author":"R Shouval","year":"2022","unstructured":"Shouval R, Alarcon Tomas A, Fein JA, Flynn JR, Markovits E, Mayer S, et al. Impact of TP53 genomic alterations in large B-Cell lymphoma treated with CD19-Chimeric antigen receptor T-Cell therapy. J Clin Oncology: Official J Am Soc Clin Oncol. 2022;40(4):369\u201381.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"22","key":"7281_CR43","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood.2018889931","volume":"133","author":"M Pascual","year":"2019","unstructured":"Pascual M, Mena-Varas M, Robles E, Garcia-Barchino M, Panizo C, Hervas-Stubbs S, et al. PD-1\/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood. 2019;133(22):2401\u201312.","journal-title":"Blood"},{"issue":"25","key":"7281_CR44","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1182\/blood.2021014007","volume":"139","author":"E Izquierdo","year":"2022","unstructured":"Izquierdo E, Vorholt D, Blakemore S, Sackey B, Nolte JL, Barbarino V, et al. Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies. Blood. 2022;139(25):3617\u201329.","journal-title":"Blood"},{"issue":"22","key":"7281_CR45","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.1158\/1078-0432.CCR-20-1523","volume":"26","author":"KD Gray","year":"2020","unstructured":"Gray KD, McCloskey JE, Vedvyas Y, Kalloo OR, Eshaky SE, Yang Y, et al. PD1 Blockade enhances ICAM1-Directed CAR T therapeutic efficacy in advanced thyroid cancer. Clin Cancer Res. 2020;26(22):6003\u201316.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07281-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07281-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07281-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:04:12Z","timestamp":1762524252000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07281-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7281"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07281-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocols were approved by the Ethics Committee of Shanghai Tongji Hospital, Tongji University, and were conducted in compliance with the principles of the Declaration of Helsinki. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read, edited, and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1247"}}